A possibility for health improvement in overweight and obese women at the stage of pregravid preparation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

About half of women planning pregnancy have too much adipose tissue, insulin resistance, hypothalamic-pituitary-ovarian axis disorders, and consequently anovulation and infertility. Objective: To assess the results of using the biologically active dietary supplement Dikirogen (myo-inositol and D-chiroinositol in a ratio of 5:1) in conjunction with combination therapy for anovulation in overweight and obese women. Materials and methods: During 2021-2022, a descriptive study assessing the results of lifestyle changes (in diet and exercises) and nutritional support (a combination of myo-inositol 1000 mg and D-chiroinositol 200 mg, folic acid 200 ig, and manganese 5 mg (Dikirogen) was conducted in the clinics of Moscow, Nizhny Novgorod, Novosibirsk, Krasnodar, Yekaterinburg, and Voronezh in 197 reproductive-aged women who had overweight or obesity and anovulation for 2-4 months. Results: The use of the biologically active dietary supplement Dikirogen in conjunction with combination therapy (diet + exercises) caused decreases in body weight by 2.5 kg, body mass index (BMI) by 0.5 kg/m2, and waist circumference by 1.75 cm. The normal menstrual cycle was 1.41 times more often observed at Visit 2. There were reductions in LH levels from 8.45 (3.91) to 6.4 (4.9; 8.8) mU/ml and in the LH/FSH ratio from 1.4 (0.9; 2.0) to 1.2 (0.8; 1.6) (p<0.0001). There were also significant decreases in fasting glucose levels from 5.0 (4.5; 5.5) to 4.8 (4.2; 5.0) mmol/l (p<0.0001) and on the number of women with fasting glucose levels above 5.1 mmol/ml by 3.07 times. During 80-90follow-up days, pregnancy occurred in 30 (15.2%) patients; at Visit 2, the ovulation test was positive in 96 (48.73%) women. Conclusion: The results of the study can recommend Dikirogen containing myo-inositol and D-chiroinositol in a ratio of 5:1, folic acid, and manganese in conjunction with combination therapy (diet, exercises) to obese and overweight women with complaints of anovulation and failure to achieve pregnancy,

Full Text

Restricted Access

About the authors

Viktor E. Radzinsky

Peoples' Friendship University of Russia

Email: radzinsky@mah.ru
Corresponding Member of the RAS, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology with the Course of Perinatology

Alina V. Solovyeva

Peoples' Friendship University of Russia

Email: av_soloveva@mam.ru
Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology with the Course of Perinatology

Vitaliy M. Kuleshov

Novosibirsk State Medical University

Email: kuleshov_vm@mail.ru
Dr. Med. Sci., Professor, Professor at the Obstetrics and Gynecology Department

Nadezhda Yu. Katkova

Volga Research Medical University

Email: katkova_nu@inbox.ru
Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Additional Vocational Education

Natalya V. Mingaleva

Kuban State Medical University

Email: mingalevan008@yandex.ru
Dr. Med. Sci., Chief Freelance Specialist in Outpatient Obstetric and Gynecological Care of the Ministry of Health of the Krasnodar Territory, Professor, Department of Obstetrics, Gynecology and Perinatology

Irina N. Korotkikh

N.N. Burdenko Voronezh State Medical University

Email: korotkikh_l950@mail.ru
Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medicine

Tatyana A. Oboskalova

Ural State Medical University

Email: oboskalova.tat@yandex.ru
Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology

Anna V. Vorontsova

Ural State Medical University

Email: a_valerevna@mail.ru
PhD, Associate Professor, Department of Obstetrics and Gynecology

References

  1. Радзинский В.Е., Боташева Т.Л., Котайш Г.А., ред. Ожирение. Диабет. Беременность. Версии и контраверсии. Клинические практики. Перспективы. М.: ГЭОТАР-Медиа; 2020. 528с.
  2. ESHRE Early Pregnancy Guideline Development Group. Recurrent pregnancy loss. 2017. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx
  3. Gomes-Serrano M., Ponath V., Preuber C., von Strandmann E.P. Beyond the extracellular vesicles: technical hurdles, achieved goals and current challenges when working on adipose cells. Int. J. Mol. Sci. 2021; 22(7): 2262. https://dx.doi.org/10.3390/ijms22073362.
  4. Ferrazzi E., Sears B. Metabolic syndrom and complications of pregnancy. Springer; 2015. https://dx.doi.org/10.1007/978-3-319-16853-1.
  5. Aune D., Saugstad O.D., Henriksen T., Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. JAMA. 2014; 311(15): 1538-46. https://dx.doi.org/10.1001/jama.2014.2269.
  6. Willis D., Mason H., Gilling Smith C., Franks S. Modulation by insulin of follicle stimulating hormone and luteinizing hormone action in human granulosa cells from normal and polycystic ovaries. J. Clin. Endocrinol. Metab. 1998; 81(1): 302-9. https://dx.doi.org/10.1210/jc.81.L302.
  7. Hillier S.G. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum. Reprod. 1994; 99(2): 188-91. https://dx.doi.org/10.1093/oxfordjournals.humrep.a138480.
  8. Franks S., Robinson S., Willis D. Nutrition, insulin and polycistic ovary syndrome. Rev. Reprod. 1996; 1: 47-53. https://dx.doi.org/10.1530/ror.0.0010047.
  9. Чернуха Г.Е., Табеева Г.И., Удовиченко М.А. Неиспользованные возможности коррекции эндокринно-метаболических нарушений при синдроме поликистозных яичников. Акушерство и гинекология. 2019; 10: 140-7. https://dx.doi.org/10.18565/aig.2019.10.140-147.
  10. Regidor P.-A., Schindler A.E., Lesoine B., Druckman R. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Horm. Mol. Biol. Clin. Investig. 2018; 34(2): /j/hmbci.2018.34. issue-2/hmbci-2017-0067/hmbci-2017-0067.xml. https://dx.doi.org/10.1515/hmbci-2017-0067.
  11. International evidence-based guideline for the assestment and managment of policistic ovary syndrome. 2018. Available at: https://www.monash.edu/__data/assets/pdf_file/0004/1412644/PCOS_Evidence-BasedGuidelines_20181009.pdf
  12. Радзинский В.Е., Соловьева А.В., Кузнецова О.А., Смирнова Т.В. Прегравидарная подготовка: доказанная польза. Эссенциальные микронутриенты в составе поливитаминных комплексов. Доктор. Ру. 2020; 19(6): 30-5. https://dx.doi.org/10.31550/1727-2378-2020-19-6-30-35.
  13. Торшин И.Ю., Майорова Л.А., Уварова Е.В., Тапильская Н.И., Громова О.А. Хемореактомный анализ стереоизомеров инозитола: различные профили фармакологического действия миоинозитола и D-хироинозитола при нарушениях женской репродуктивной системы. Вопросы акушерства, гинекологии и перинатологии. 2020; 19(5): 57-69. https://dx.doi.org/10.20953/1726-1678-2020-5-57-69.
  14. Munro M.G., Critchley H.O.D., Fraser I.S.; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int. J. Gynecol. Obstet. 2018; 143(3): 393-408. https://dx.doi.org/10.1002/ijgo.12666.
  15. Радзинский В.Е., Соловьева А.В., Алейникова Е.Ю., Смирнова Т.В., Кузнецова О.А. Беременность и роды у женщин с железодефицитной анемией легкой степени, выявленной в I триместре. Акушерство и гинекология: новости, мнения, обучение. 2021; 9(3, Приложение): 6-13. https://dx.doi.org/10.33029/2303-9698-2021-9-3suppl-6-13.
  16. Радзинский В.Е., ред. Анемии и репродуктивное здоровье. М.: Status Praesens; 2019. 200 с.
  17. Vahratian A., Smith Y.R. Should access to fertility-related services be conditional on body mass index? Hum. Reprod. 2009; 24(7): 1532-7. http://dx.doi.org/10.1093/humrep/dep057.
  18. Franks S., Hardy K. What causes anovulation in polycystic ovary syndrome? Curr. Opin. Endocr. Metab. Res. 2020; 12: 59-65. https://dx.doi.org/10.1016/j.coemr.2020.03.001.
  19. Chavarro J.E., Rich-Edwards J.W., Rosner B.A., Willett W.C. Diet and lifestyle in the prevention of ovulatory disorder infertility. Obstet. Gynecol. 2007; 110(5): 1050-8. https://dx.doi.org/10.1097/01.AOG.0000287293.25465.e1.
  20. Rich-Edwards J.W., Spiegelman D., Garland M., Hertzmark E., Hunter D.J., Colditz G.A. et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology. 2002; 13(2): 184-90. https://dx.doi.org/10.1097/00001648-200203000-00013.
  21. Obirikorang C., Owiredu W.K.B.A., Adu-Afram S., Acheampong E., Asamoah E.A., Antwi-Boasiakoh E.K., Owiredu E. Assessing the variability and predictability of adipokines (adiponectin, leptin, resistin and their ratios) in non-obese and obese women with anovulatory polycystic ovary syndrome. BMC Res. Notes. 2019; 12(1): 513-21. https://dx.doi.org/10.1186/s13104-019-4546-z.
  22. Sylvia K.E., Lorenz T.K., Heiman J.R., Demas G.E. Physiological predictors of leptin vary during menses and ovulation in healthy women. Reprod. Biol. 2018; 18(1): 132-6. https://dx.doi.org/10.1016/j.repbio.2018.01.011.
  23. Ahrens K., Mumford S.L., Schliep K.C., Kissell K.A., Perkins N.J., Wactawski-Wende J., Schisterman E.F. Serum leptin levels and reproductive function during the menstrual cycle. Am. J. Obstet. Gynecol. 2014; 210(3): 248-e1. https://dx.doi.org/10.1016/j.ajog.2013.11.009.
  24. Boyd M., Ziegler J. Polycystic ovary syndrome, fertility, diet, and lifestyle modifications: a review of the current evidence. Top. Clin. Nutr. 2019; 34(1): 14-30. https://dx.doi.org/10.1097/TIN.0000000000000161.
  25. McGrice M., Porter J. The effect of low carbohydrate diets on fertility hormones and outcomes in overweight and obese women: a systematic review. Nutrients. 2017; 9(3): 204. https://dx.doi.org/10.3390/nu9030204.
  26. Azziz R., Carmina E., Chen Z., Dunaif A., Laven J.S., Legro R.S. et al. Polycystic ovary syndrome. Nat. Rev. Dis. Prim. 2016; 2: 16057. https://dx.doi.org/10.1038/nrdp.2016.57.
  27. Barbe A., Bongrani A., Mellouk N., Estienne A., Kurowska P., Grandhaye J. et al. Mechanisms of adiponectin action in fertility: an overview from gametogenesis to gestation in humans and animal models in normal and pathological conditions. Int. J. Mol. Sci. 2019; 20(7): 1526. https://dx.doi.org/10.3390/ijms20071526.
  28. Teede H., Misso M., Tassone E.C., Dewailly D., Ng E.H., Azziz R. et al. Anti-mullerian hormone in PCOS: A review informing international guidelines. Trends Endocrinol. Metabol. 2019; 30(7): 467-78. https://dx.doi.org/10.1016/j.tem.2019.04.006.
  29. Majunder A.L., Biswas B.B., eds. Biology of inositols and phosphoinositides. Series: Subcellular biochemistry. Springer; 2006 January; vol.39. https://dx.doi.org/10.1007/0-387-27600-9.
  30. Milewska E.M., Czyzyk A., Meczekalski B., Genazzani A.D. Inositol and human reproduction. From cellular metabolism to clinical use. Gynecol. Endocrinol. 2016; 32(9): 690-5. https://dx.doi.org/10.1080/09513590.2016.1188282.
  31. Ravanos K., Monastra G., Pavlidou T., Gouda kou M., Prapas N. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur. Rev. Med. Pharmacol. Sci. 2017; 21(23): 5491-8. https://dx.doi.org/10.26355/eurrev_201712_13940.
  32. Ozay O.E., Ozay A.C., Qagliyan E., Okyay R.E., Gulekli B. Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: A prospective, controlled, randomized trial. Gynecol. Endocrinol. 2017; 33(7): 524-8. https://dx.doi.org/10.1080/09513590.2017.1296127.
  33. Sacchi S., Marinaro F., Tondelli D., Lui J., Xella S., Mars ell a T. et al. Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol. Reprod. Biol. Endocrinol. 2016; 14(1): 52. https://dx.doi.org/10.1186/s12958-016-0189-2.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies